Clinical Trial Update: Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) [Phase 1]

View source ↗

Summary

Phase 1 trial completed to determine the maximum tolerated dose of low-dose interferon-alpha in combination with nilotinib for patients with Philadelphia chromo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Interferon alpha (low-dose) (Interferon alpha)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Phase 1 | Status: COMPLETED